Biosion USA, Inc., a global R&D biotechnology company, today announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen, Inc., a leader in developing next generation ADCs. In the joint research effort, Biosion will leverage its proprietary SynTracer
